Psychedelics Intelligence — Stratum Collective

PSYCHEDELICS STRATEGY INTEL

Regulatory trajectory × Stratum positioning analysis

WINDOW SIGNAL May 4, 2026

🟢

VERDICT: NOT A PIVOT — A SEQUENCED EXTENSION

The psychedelic therapy RCM market is 18–36 months from being real. The corpus can't be built yet because insurance claims don't exist yet. But the window to establish first-mover positioning is open now. The move is Spravato corpus (near-term revenue) + clinical necessity framework participation (zero-cost positioning) + psilocybin corpus intake at FDA approval (2026–2027). Stratum's thesis — high-variability clinical scenarios that volume-optimized RCM AI fails at — fits psychedelic therapy better than anything else in behavioral health.

The most complex denial patterns in behavioral health history are 18 months away. Stratum should be the infrastructure they run on.

EO Signed

Apr 18

Trump fast-track EO, 2026

Est. FDA Approval

Q1 '27

COMPASS psilocybin TRD

Coverage Opens

2028

Commercial payer est.

Market 2026

$5.5B

→ $26.4B by 2035

Corpus White Space

Competitors in denial intel

NOW — Spravato Wedge

EXECUTE

Esketamine (Spravato) is FDA-approved, has Category I CPT codes, is covered by all major commercial payers with complex PA requirements. Same clinical population as psilocybin (TRD). Every Spravato denial precedent is a psilocybin template. Build the corpus now; generate revenue now.

NOW — Positioning Signal

PUBLISH

No RCM company is publishing on psychedelic denial intelligence. The clinical necessity frameworks are being written now by working groups (NNDC, AMA CPT panel). Publish white paper. Enter those rooms. Oregon/Colorado operators will need RCM infrastructure in 18 months — be the company they know before they need you.

2027 — Corpus Intake

MONITOR

At COMPASS NDA filing (Q4 2026), activate beta corpus partner relationships with clinic operators. First psilocybin coverage denials emerge 2027–2028. Stratum enters with 12+ months of precedent intelligence vs. zero for any competitor entering at that moment.

Regulatory Timeline — Compound Status

Compound	Company / Program	Status	Earliest FDA Decision	Coverage Implication
Psilocybin (TRD)	COMPASS Pathways (COMP360)	Phase 3 complete — 2 positive trials	Late 2026 / Q1 2027	First commercial coverage decisions 2027–2028
Psilocybin (MDD)	Usona + others	Phase 3 ongoing	2027–2028	Broader coverage follows COMPASS precedent
Methylone (PTSD)	MAPS successor entity	Priority voucher issued	2027+	Uncertain — MDMA rejection casts shadow
MDMA	Lykos Therapeutics	Complete Response Letter (rejected 2024)	Unknown — resubmission pending	Not imminent
Ibogaine	Various	Phase 1 trial approved	2029+	Cardiac safety concerns; distant
Esketamine (Spravato)	Janssen / J&J	FDA approved 2019	Live — Category I CPT codes exist	Covered now with PA at UHC, Cigna, Anthem, Horizon
Ketamine (IV)	Various clinics	Legal / no FDA psychiatric approval	None pending	Mostly self-pay; some off-label coverage

Key Insight: MDMA Rejection Is a Feature, Not a Bug

FDA's 2024 rejection of MDMA-assisted therapy proves the agency will hold the line on safety and efficacy. Every approval that does happen carries clinical legitimacy — which means payer coverage will follow with clear medical necessity criteria, not vague "we'll see." The MDMA rejection gives payers a template for what they'll demand before covering any psychedelic: robust Phase 3 data, REMS-equivalent safety monitoring, contraindication documentation. Psilocybin's two consecutive Phase 3 successes are meaningful precisely because MDMA failed the same bar.

The RCM Problem Forming in Real Time

Why Psychedelic Therapy Will Be the Hardest RCM Billing in Behavioral Health History

6–8 hour dosing sessions already exceed Medically Unlikely Edits (MUEs) for standard psychotherapy CPT codes. Category III codes (0820T–0823T) exist but are tracking codes only — not reimbursable under Medicare, Medicaid, or commercial insurance. No Category I CPT status until 18–24 months post-FDA approval at minimum. "Investigational," "no medical necessity," and "protocol non-adherence" will be the dominant denial vectors. Payers are already building internal task forces — prior authorization will be their first instrument, and it will be more complex than any existing BH PA schema.

Structural Complexity Drivers

6–8 hour session duration

Exceeds MUE limits for all existing psychotherapy CPT codes — no clean billing pathway exists without Category I codes

Category III codes (tracking only)

0820T–0823T introduced by AMA — zero reimbursability, but required for tracking. Category I upgrade: 18–24 months post-approval

No standard of care comparators

Payers have no internal medical necessity criteria to reference — they'll write them from scratch, with maximum conservatism

Concurrent psychotherapy mandates

Integration therapy (before + after dosing) requires separate billing — payers will audit session bundling, split billing, and care coordination

REMS-equivalent safety monitoring

Will require facility certification, prescriber registration, patient monitoring documentation — each a denial vector if documentation is incomplete

The Spravato Analog — What Psilocybin Will Look Like

Spravato (esketamine) received FDA approval in 2019. In 2026 — 7 years later — it still faces:

Step therapy mandates at all major payers

Must document failure of ≥2 antidepressants — same step-therapy logic will govern psilocybin

Prior authorization at every commercial payer

UHC effective 5/1/2025, Cigna, Anthem, Horizon, Florida Blue all require active PA — and have distinct criteria

High initial denial → appeal success pattern

"Many approvals happen on appeal once the plan sees a complete file" — J&J publishes a dedicated Exceptions & Appeals Guide

REMS program compliance as denial vector

Sessions must occur in certified healthcare settings with 2-hour post-dose monitoring — non-compliance = automatic denial

BH Denial Baseline Stratum Already Operates In

Metric	Current (2025–2026)	Psychedelic Trajectory
BH claims growth	+17% in 2025 — payer scrutiny accelerating	Add psychedelic claims volume post-approval: further acceleration
Top denial code	CO-197 — no authorization on file	Psychedelics will generate CO-197 at far higher initial rates — novel modality, payers unfamiliar
Revenue leakage	15–30% of collectible revenue lost annually	Psychedelic practices (higher per-session cost) will face proportionally larger dollar losses
Primary challenge	Prior auth denials for residential + PHP/IOP	Prior auth for novel 6-hour dosing sessions will be the hardest PA scenario in BH

Clients served (Q1 2025)	1,500+ per quarter
Session cost	$1,200 – $3,000
Group sessions	$300 – $500
Insurance coverage	None — 100% self-pay
Income skew	Majority >$95K/yr
Why no coverage	Federally Schedule I; payers await FDA approval + CMS precedent

ARPA-H allocation (EO-directed)	$50M minimum
Target	States with active psychedelic programs
HALT Fentanyl Act (2025)	Streamlined Schedule I research authorization
Priority voucher benefit	FDA review compressed to ~1–2 months post-NDA
Political champions	Trump (EO), RFK Jr. (HHS), Makary (FDA)
Durability driver	Ibogaine for veteran PTSD — bipartisan, un-defundable

Critical Analysis — The Honest Read

The Case Against — What You Need to Hear First

The corpus doesn't exist yet and can't be built. Stratum's thesis is precedent-based intelligence — actual denial decisions and clinical necessity reasoning encoded across thousands of cases. For psychedelic therapy, those cases don't exist. Oregon is 100% self-pay. No insurance claims means no denials means no corpus. "First corpus in psychedelic denial intelligence" is a category error — you'd be building documentation infrastructure for a market that has generated zero insurance documentation.

Stratum has no revenue yet. H1 (knowledge asymmetry proves real) is unvalidated. Adding an 18-month speculative extension before locking paying customers in the primary BH market is how founders lose focus at exactly the wrong moment.

The timeline risk is real. MDMA got rejected. Ibogaine has cardiac risk concerns. If COMPASS hits a manufacturing issue or safety signal, NDA approval slips to 2028. Commercial coverage follows 12–18 months after that. Medicaid coverage (the dominant BH payer) could be 5+ years from now in most states.

The Reframe That Changes the Math

The real opportunity isn't the psychedelic corpus. It's the clinical necessity framework.

By the time psilocybin coverage begins, payers will have already written their medical necessity criteria. The organizations writing those criteria now — NNDC, AMA CPT Editorial Panel, OHA Psilocybin Services Division — are drafting the policy that will generate Stratum's future corpus. If Stratum is a participant in that process, you're not waiting for the corpus to appear — you're helping write the criteria the corpus will be scored against.

Zero RCM companies are making this move. Every BH RCM vendor is looking backward at existing claims data. Stratum would be the only one at the table where future claims criteria are being defined. That's a different kind of moat.

Move	Horizon	What It Requires	Revenue	Risk
Spravato denial corpus	Now	Existing claims data + payer PA policies (public)	Yes — near-term	Low — market exists
Clinical necessity framework positioning	Now – 6 months	White paper + working group participation	No — brand/inbound	Very low — zero cost
Psilocybin corpus intake	2027–2028	FDA approval + coverage decisions to exist	Yes — longer-term	Medium — timeline dependent

Strategic Moves — Insertion Points

MOVE 01 · EXECUTE NOW

Spravato Corpus — Near-Term Revenue + Psychedelic Proof of Concept

Build Spravato (esketamine) denial pattern corpus: step-therapy failure documentation requirements, TRD diagnostic criteria payers require, concurrent psychotherapy mandates, REMS program compliance denials. J&J publishes a Prior Authorization Toolkit and an Exceptions & Appeals Guide — these are public documents that encode the appeal logic Stratum should systematize. Map clinical necessity criteria across all major payers (UHC effective 5/1/2025, Cigna, Anthem, Horizon, Florida Blue — all public).

Why it matters strategically: When psilocybin coverage begins, it will mirror Spravato's pathway exactly. Every Spravato denial precedent is a psilocybin precedent template. Target: 300–400 specialized psychiatric and TRD clinics that administer Spravato — the same clinics that will be first movers on psilocybin.

⏱ Horizon: Now · Revenue: Yes · Risk: Low

MOVE 02 · PUBLISH NOW

White Paper: "Before the Precedents Exist: Building Clinical Necessity Infrastructure for Psychedelic-Assisted Therapy"

Audience: BH RCM directors, psychedelic clinic operators, payer medical policy teams, healthcare investors. Argument: (1) The PA system for novel BH modalities is broken by design — Spravato is the proof. (2) Psychedelic therapy will face a more complex denial landscape than any prior BH innovation. (3) Clinical necessity criteria are being written now, before any payer has covered a single session — this is the leverage point. (4) Stratum's corpus architecture is the infrastructure this market needs.

Distribution: Psychedelic Alpha (industry trade publication), MAPS network, ASKP³ (American Society of Ketamine Physicians), behavioral health VC networks.

⏱ Horizon: 60 days · Revenue: No (inbound) · Risk: Very low

MOVE 03 · ENTER NOW

Clinical Necessity Working Groups — Be in the Room Where Criteria Are Written

Organization	What They're Doing	Stratum's Entry Point
NNDC	Published psilocybin consensus statement (Lancet eClinicalMedicine, 2025)	Submit commentary; request working group participation
AMA CPT Editorial Panel	Will vote on 0820T–0823T Category I promotion post-approval	Monitor comment period; submit provider impact testimony
Oregon Health Authority	Running first-in-nation psilocybin program; publishing quarterly data	Build relationship with OHA data team; position as billing infrastructure
MACPAC / CMS	Will write Medicare coverage determination post-approval	Track NCD timeline; submit comment on medical necessity standards

⏱ Horizon: 90 days · Revenue: No (positioning) · Risk: Very low

MOVE 04 · CULTIVATE NOW

Oregon/Colorado Operator Relationships — Be the Company They Call in 18 Months

Oregon: 1,500+ clients per quarter, growing. Every one of those clients is self-pay today. Every one becomes a billable claim the moment coverage begins. The pitch: "You're building a practice on a self-pay model that will transition to insurance reimbursement within 24 months. The denial patterns that emerge will define your revenue for the next decade. Stratum is building the precedent intelligence infrastructure so you learn from everyone's denials, not just your own." They don't need RCM today — they need to know who they're calling in 18 months.

⏱ Horizon: Ongoing · Revenue: No (pipeline) · Risk: Very low

MOVE 05 · EXECUTE THIS WEEK

Evidence Registry Extension — Add Psychedelic-Adjacent Clinical Necessity Evidence

Add a new category to the Stratum Evidence Registry: Psychedelic-Adjacent Clinical Necessity Evidence. Seed with: (1) Spravato clinical necessity criteria across 5 major payers — all published, all public. (2) AMA Category III code definitions (0820T–0823T) and documentation requirements. (3) NNDC consensus statement clinical criteria for appropriate psilocybin candidates. (4) Oregon OHA facilitator service protocols (de facto clinical necessity framework for state-regulated access). (5) MDMA rejection CRL — FDA stated concerns become the clinical necessity contraindications payers will adopt.

None of this requires waiting for insurance claims. It's the framework documentation that will structure the corpus when claims begin.

⏱ Horizon: This week · Revenue: No (corpus readiness) · Risk: None

The Three-Move Sequence

NOW	Spravato + Position	Spravato corpus (revenue-generating) + white paper + working group entry + Oregon/Colorado relationship building	Revenue	Low cost
Q4 2026	Activate	COMPASS NDA filing triggers active monitoring. Position Stratum to intake first psilocybin coverage denials as beta corpus partner with clinic operators built over prior 12 months	Pre-revenue	Timeline
2027–28	Corpus Intake	Real coverage, real denials, real corpus. Stratum enters with 12+ months of precedent intelligence vs. zero for any competitor entering at this moment	Revenue	Market proven

Risk Factors — Track These

RISK 01 · HIGH · MONITOR MONTHLY

FDA Timeline Slippage

COMPASS targets late 2026 NDA submission. Any manufacturing issue, safety signal, or CMC (Chemistry, Manufacturing, Controls) gap delays approval to 2028+. Coverage follows 12–18 months after approval. Market could open 3+ years later than expected. Monitor: COMPASS quarterly filings, COMP006 Part B durability data (expected early Q3 2026).

RISK 02 · MEDIUM · STRUCTURAL

Payer Blanket Exclusions — Standard Playbook for Novel Therapeutics

Standard payer playbook: approve in principle, exclude in practice via step-therapy and medical necessity criteria that few patients can meet. MDMA's rejection gives payers cover to be maximally conservative. Even with FDA approval, psilocybin could face 2–3 years of "non-covered — investigational" determinations before commercial coverage becomes routine. The Spravato 7-year timeline is the precedent. Implication: This risk is actually bullish for Stratum — the more complex the payer environment, the more Stratum's corpus matters.

RISK 03 · LOW · POLITICAL

Federal Policy Reversibility

The EO was signed April 2026. A political shift or RFK Jr. departure could stall implementation. However: the veteran/PTSD framing is the most politically durable in healthcare policy. Ibogaine for veterans has explicit cross-aisle support. The FDA actions (priority vouchers, rolling NDA review) are now institutional — harder to reverse than executive orders. Risk rated low, not zero. Monitor: RFK Jr. tenure, midterm political landscape, DOD/VA psychedelic research funding.

RISK 04 · MEDIUM · FOCUS

Stratum Pre-Revenue Position — Focus Dilution

Adding a speculative 18-month horizon positioning play before H1 (knowledge asymmetry) is validated risks diluting focus at the worst possible time. The Spravato wedge mitigates this — it's not speculative, it's an adjacent market that exists today. White paper and working group participation are low-cost. The risk is if Stratum treats psychedelics as a primary market strategy before proving the core BH denial market. Guardrail: Psychedelics positioning is a parallel track at <15% of time allocation until H1 is validated.